Sorbitol Is a Severity Biomarker for <scp>PMM2‐CDG</scp> with Therapeutic ImplicationsAnna N. Ligezka, Éva Morava, Ethan Perlstein et al.|Annals of Neurology|2021Cited by 57
Expanding the phenotypic spectrum of FINCA (fibrosis, neurodegeneration, and cerebral angiomatosis) syndrome beyond infancyChristina Rapp, Matthias Griese, Ine Van Dijck et al.|Clinical Genetics|2021Cited by 24
Spontaneous improvement of carbohydrate-deficient transferrin in PMM2-CDG without mannose observed in CDG natural history studyPeter Witters, Éva Morava, Christina Lam et al.|Orphanet Journal of Rare Diseases|2021Cited by 21
Frontiers in congenital disorders of glycosylation consortium, a cross-sectional study report at year 5 of 280 individuals in the natural history cohortChristina Lam, Roni Zemet, Audrey Squire et al.|Molecular Genetics and Metabolism|2024Cited by 19
Additional file 1 of Spontaneous improvement of carbohydrate-deficient transferrin in PMM2-CDG without mannose observed in CDG natural history studyPeter Witters, Éva Morava, Christina Lam et al.|Figshare|2021Cited by 0